Format

Send to

Choose Destination
Aging (Albany NY). 2016 Feb;8(2):304-13.

Inhalational Alzheimer's disease: an unrecognized - and treatable - epidemic.

Author information

1
Easton Laboratories for Neurodegenerative Disease Research, Department of Neurology, University of California, Los Angeles, CA 90095, USA.
2
Buck Institute for Research on Aging, Novato, CA 94945, USA.

Abstract

Alzheimer's disease is one of the most significant healthcare problems today, with a dire need for effective treatment. Identifying subtypes of Alzheimer's disease may aid in the development of therapeutics, and recently three different subtypes have been described: type 1 (inflammatory), type 2 (non-inflammatory or atrophic), and type 3 (cortical). Here I report that type 3 Alzheimer's disease is the result of exposure to specific toxins, and is most commonly inhalational (IAD), a phenotypic manifestation of chronic inflammatory response syndrome (CIRS), due to biotoxins such as mycotoxins. The appropriate recognition of IAD as a potentially important pathogenetic condition in patients with cognitive decline offers the opportunity for successful treatment of a large number of patients whose current prognoses, in the absence of accurate diagnosis, are grave.

KEYWORDS:

biomarkers; biotoxins; chronic inflammatory response syndrome; cognition; dementia; mycotoxins; neurodegeneration

PMID:
26870879
PMCID:
PMC4789584
DOI:
10.18632/aging.100896
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Impact Journals, LLC Icon for PubMed Central
Loading ...
Support Center